Dr. Lal PathLabs Releases FY26 Annual Report Highlighting Innovation
Dr. Lal PathLabs Ltd has released its Annual Report for the Financial Year 2025-26, detailing its performance and strategic initiatives. The report emphasizes the company's focus on innovation and precision in diagnostics, positioning itself at the forefront of modern healthcare. Key financial highlights for FY26 include revenue from operations of ₹27,629 million and a reported Profit After Tax (PAT) of ₹5,098 million. The company also reported an Earnings Per Share (EPS) of ₹30.2 and a Return on Capital Employed (ROCE) of 44% (excluding cash and investments). Operationally, Dr. Lal PathLabs expanded its network with 312 labs, including 53 NABL-accredited and 2 CAP-accredited facilities, serving over 30.3 million patients and processing 94.5 million samples. The report also covers ESG initiatives, including CSR spending of ₹102.2 million and a cumulative solar generation capacity of 3.22 MW.
Key Highlights
- FY26 revenue from operations reached ₹27,629 million.
- Reported PAT for FY26 stood at ₹5,098 million.
- Company expanded its network to 312 labs, serving 30.3 million patients.
- Introduced 13 new advanced diagnostic solutions in FY26.
- FY26 ROCE was 44% (excluding cash and investments).
Price Impact
More from LALPATHLAB